Thursday, May 08, 2008 11:50:59 AM
C Chitti Pantulu / DNA MONEY
Wednesday, 07 May , 2008, 09:52
The Orchid Chemicals lesson has not been lost on Dr Reddy's Laboratories.
More India business stories
The Hyderabad-based company's promoters are seeking to ringfence India's second largest pharma player.
Dr Reddy's vice-chairman and chief executive G V Prasad told DNA Money that the company's board, at a meeting on January 25, had approved a preferential issue of share warrants up to 5% of the existing equity of DRL, exercisable into an equal number of equity shares.
"We have not exercised that option because we haven't approached shareholders yet," he said, adding that the option may be looked at now.
The Bombay Stock Exchange's records show that promoters held 25.14% in Dr Reddy's as on March 31, 2008.
Asked about hostile bids, Prasad said the management was hoping to create good shareholder value and through this, keep such threats low.
"The only way (to avoid hostile bids) is to keep the share price from dipping. It shouldn't become low enough to attract such bids," he said.
But Dr Reddy's shares haven't exactly been soaring on the BSE.
The shares fell 8.49% to Rs 643.80 on Tuesday. After touching a high of Rs 747 on January 2, the company's shares have dipped 14% to date. Prasad blames the problems being faced by Betapharm, the German generics maker it acquired in 2006 to the drag on Dr Reddy's. Price reforms introduced by Germany in April have made life difficult.
The other factors that have hurt its performance are increasing rebates to insurance companies and a change in the composition of Betapharm's top products.
More India business stories
Prasad, however, felt that the downswing is temporary and won't hurt the company in the long term.
http://sify.com/finance/fullstory.php?id=14668506
Recent RDY News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2024 05:38:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2024 06:43:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2024 06:35:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2024 11:53:50 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/06/2024 12:41:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/06/2024 11:11:55 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/03/2024 11:15:41 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/02/2024 11:28:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2024 11:19:04 AM
- Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma • Business Wire • 11/28/2024 11:15:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/27/2024 01:39:08 PM
- Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market • Business Wire • 11/26/2024 01:07:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/26/2024 11:19:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/26/2024 11:08:11 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2024 11:06:45 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2024 11:24:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/19/2024 01:02:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2024 12:11:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/07/2024 11:35:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2024 11:11:48 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2024 11:05:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/05/2024 07:14:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/05/2024 06:40:56 PM
- Dr. Reddy’s Q2 & H1FY25 Financial Results • Business Wire • 11/05/2024 02:59:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/04/2024 05:10:26 PM
Basanite, Inc. to Open New Production and Distribution Facility in Northeast Ohio • BASA • Jan 2, 2025 8:28 AM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM